Agenus announced a private placement expected to raise approximately $85 million in gross proceeds at a combined purchase price of $3.69 per unit, alongside Series A and Series B warrants that could generate up to an additional $255 million if fully exercised. Closing is expected on Jul 15, 2026. In a related move, the company granted registration rights to investors, committing to file a resale registration statement within 45 days of closing and to seek effectiveness within 90 days. Proceeds will support the Phase 3 neoadjuvant BOT+BAL program in MSS colon cancer.
Agreement 1: Agenus Launches $85 Million Private Placement, Warrants Add Up to $255 Million Upside
- Agreement type: Securities Purchase Agreement for private placement of common stock, pre-funded warrants, and accompanying warrants
- Counterparty: Institutional and Accredited Investors
- Signed / Effective: Jul 13 2026 / Jul 15 2026
- Duration / Termination: At will
- Reason: Fund Phase 3 BOT+BAL neoadjuvant MSS colon cancer program
Agreement 2: Agenus Grants Registration Rights to Investors Following Private Placement
- Agreement type: Registration Rights Agreement for resale of common and warrant shares
- Counterparty: Institutional and Accredited Investors
- Signed / Effective: Jul 13 2026 / Jul 13 2026
- Duration / Termination: Until resale registration effective and maintained
- Reason: Provide liquidity for private placement investors
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.